Press Release
| Date | Medium | Content |
| 2011/10/13 | - | DNAVEC Corporation announces the publication of a research paper in the journal Nature reporting a gene repair therapy using iPS cells from patients with severe monogeneic disease |
| 2011/4/27 | NIHON KEIZAI SHINBUN | Launching a Kit for iPS cell Generation to the Market Outside of Japan |
| 2010/11/10 | NIHON KEIZAI SHINBUN | DNAVEC concludes a licensing agreement with a Biotech Company of China on retinitis pigmentosa therapeutics. |
| 2010/06/15 | - | On the launch of the iPS cell preparation kit |
| 2009/10/08 | - | Notice on the offer of chromosomal damage-free iPS cell preparation kit |
| 2009/10/02 | - | Notice on the academic publication regarding the method for the preparation of chromosomal damage-free iPS cells. |
| 2009/04/29 | - | On the technological partnership with Daiichi Sankyo Co., Ltd. regarding antibody therapeutics |
| 2009/04/09 | - | On the conclusion of a collaborative research agreement with Sichuan University of China regarding gene therapeutics for glaucoma |
| 2008/04/01 | - | DNAVEC concludes a collaborative development agreement with Chinese Academy of Sciences on the development of Avian Influenza vaccine. |
| 2007/05/25 | - | DNAVEC concludes a licensing agreement with SiBiono of China on AIDS vaccine. |
| 2006/07/04 | - | A new concept of gene therapy enters a clinical study: the Japan-made gene therapy vector, Sendai virus vector, was administered to a patient for the first time at the Kyushu University Hospital. |
| 2006/03/31 | - | DNAVEC and Eisai sign an agreement on drug discovery research for the development of gene vaccine for Alzheimer’s disease. |
| 2006/01/16 | - | DNAVEC was granted the patent "AIDS virus vaccines using Sendai virus vector" in China. |
| 2005/11/15 | NIHON KEIZAI SHIMBUN (morning edition p12) |
HIV Vaccine development in China: clinical trial to start in 2006. |
| 2005/10/12 | - | MHLW approves the Kyushu University Hospital's plan for a clinical study of gene therapy: the start of a new concept of gene therapy. |
| 2005/08/24 | NIKKEI SANGYO SHIMBUN (morning edition p1) |
Vaccines change the world of medicine: Competition for the drugs for Alzheimer’s disease heats up. |
| 2005/06/29 | - | DNAVEC was granted the master patent of Sendai virus vectors in major countries. |
| 2005/06/17 | - | DNAVEC and Medical & Biological Laboratories Co., Ltd (MBL) found a joint venture in Beijing, China. |
| 2005/06/09 | - | DNAVEC and National Institute for Longevity Sciences announce a joint development of intranasal vaccines for the treatment of Alzheimer’s disease. |
| 2005/04/13 | - | DNAVEC announces the launching of the "CKD New Generation Cancer Gene Therapy Research Consortium" involving Chiba University, Kyusyu University and DNAVEC, and the opening of a core research chair for the program sponsored by DNAVEC. |
| 2005/04/11 | NIKKEI SANGYO SHIMBUN (morning edition p12) |
“Social Lounge: Surviving by multinational expansion,” an interview with Dr. Mamoru Hasegawa, President and CEO of DNAVEC. |
| 2005/02/17 | - | DNAVEC concludes a joint research agreement with Kringle Pharma, Inc. on the development of gene medicine. |
| 2004/12/07 | - | DNAVEC announces business alliance with Medical & Biological Laboratories Co., Ltd. (MBL) on the use of Sendai virus vector. |
| 2004/12/01 | - | DNAVEC concludes an licensing agreement on a gene therapeutic medicine to Beijing Pharmaceutical Group Co., Ltd. |
| 2004/10/07 | NIHON KEIZAI SHIMBUN (morning edition p16) |
DNAVEC announces a capital increase of ¥1,900 Million funded by Dream Incubator Inc. |
| 2004/05/01 | WEEKLY TOYOKEIZAI 2004.5.1-8 |
Hideaki Sena’s monthly interview series, "Invitation to Science Part 2" with Dr. Mamoru Hasegawa, President and CEO of DNAVEC, "Gene therapy will become something like drugs for common cold." |
| 2003/11/07 | NIHON KEIZAI SHIMBUN (morning edition p17) |
An AIDS vaccine will be developed by Japan-China collaboration; DNAVEC Res. Inc. receives a promising gene. |
| 2003/07/07 | NIKKEI SANGYO SHIMBUN (morning edition p9) |
RNA opens a new avenue to bio-business part1: Safer gene therapy using Sendai virus vectors; clinical trials planned at universities in Japan and overseas. |
| 2003/06/26 | NIHON KEIZAI SHIMBUN, Ibaraki Section (morning edition p41) |
DNAVEC Research Inc. develops a "carrier" of genes (North Kanto VB file). |
| 2003/06/13 | NIKKEI SANGYO SHIMBUN (morning edition p10) |
DNAVEC Research Inc. test-produces SARS vaccine by August in collaboration with Beijing University of Technology; animal experiments are planned in China. |
| 2002/08/26 | NIKKEI BIOTECH | DNAVEC Research Inc. receives a grant for CF gene therapy using Sendai virus vectors. |
| 2001/09/03 | YAKUJI NIPPO | DNAVEC Research Inc. develops a new viral vector for the gene therapy for Critical Limb Ischemia. |
| 2001/08/02 | NIKKEI SANGYO SHIMBUN (morning edition p11) |
DNAVEC Research Inc. transfers genes into monkey ES cells with an efficiency of 90%. |
| 2001/07/20 | NIHON KEIZAI SHIMBUN (morning edition p17) |
DNAVEC Research Inc. develops an effective “carrier” for gene therapy; clinical trial planned in UK. |
| 2001/07/02 | NIKKEI BIOTECH | DNAVEC and Kyushu University forms a research consortium aiming at utilization of DNAVEC’s Sendai virus vectors. |
| 2001/02/05 | NIKKEI SANGYO SHIMBUN (morning edition p11) |
DNAVEC Research Inc. develops a Japan-made vector for gene therapy. |
| 2000/11/18 | NIHON KEIZAI SHIMBUN (morning edition p13) |
Gene therapy; accelerated commercialization targeting lifestyle-related diseases. |
| 2000/09/25 | NIHON KEIZAI SHIMBUN (morning edition p17) |
DNAVEC Research Inc. develops a high performance gene carrier, a Japanese original. |
